Jill Corre

56PUBLICATIONS
245CO-AUTHORS
Medical mycologyPredictive and prognostic markersMedical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (56)

|Aug 17, 2026
Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results.

|Jul 02, 2026
Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma.

|Jun 04, 2026
PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma.

|Mar 27, 2026
FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Bastien Jamet, Shamimeh Ahrari, Sonja Zweegman

|Jan 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

Holly Lee, Sungwoo Ahn, Gerone A Gonzales

|Dec 11, 2025
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.

Anil Aktas Samur, Jill Corre, Srikanth Talluri

Pageof 10

Frequent Collaborators

31 joint publications

Aurore Perrot

19 joint publications

Xavier P Leleu

14 joint publications

Herve Avet-Loiseau

9 joint publications

Cyrille Touzeau